talkbio – Page 2

Draft MAHA Commission Report Outlines Broad Vaccine Framework and Addresses Childhood Chronic Disease

3 days ago talkbio0Tagged CDC, Centers for Disease Control and Prevention (U.S.), childhood vaccine schedule, Chronic disease, Commission, draft report, Drug Industry, MAHA, medical freedom, overmedicalization, vaccine framework, vaccine injuries

MAHA Commission; draft report; vaccine framework; childhood vaccine schedule; vaccine injuries; medical freedom; conflicts of interest; CDC; chronic disease; overmedicalization; pharmaceutical industry

Tariffs and MFN Policy Power a Broad, Confusing Pharma War

3 days ago talkbio0Tagged Drug Industry, drug manufacturing, Drug Prescriptions, Medicaid, MFN, Nation, onshoring, pharma innovation, Policy, Trump administration

tariffs; Most Favored Nation (MFN) policy; prescription drug pricing; pharmaceutical industry; Trump administration; drug manufacturing; onshoring; Medicaid; pharma innovation

Viking Therapeutics Shares Crash After Obesity Pill VK2735 Delivers 12% Weight Loss, But Side Effects and Discontinuations Raise Concerns

3 days ago talkbio0Tagged Adverse event, aspects of adverse effects, Clinical Trials, Contraceptives, Oral, drug efficacy, gastrointestinal, Obesity, Stock Crash, Viking, VK2735, Weight Loss

Viking Therapeutics; VK2735; obesity pill; weight loss; clinical trial; stock crash; side effects; adverse events; gastrointestinal; drug efficacy

FDA Rejects PTC’s Vatiquinone Application for Friedreich’s Ataxia, Requests Further Studies

3 days ago talkbio0Tagged Clinical Research, Complete Response Letter, drug efficacy, factor IX, Friedreich 's ataxia, Rejection, United States Food and Drug Administration, vatiquinone

FDA rejection; PTC Therapeutics; vatiquinone; Friedreich’s ataxia; complete response letter; drug efficacy; additional clinical studies

CSL Announces Vaccine Unit Spin-Off and Major Workforce Cuts

3 days ago talkbio0Tagged cost-cutting, demerger, Seqirus, SMPX gene, strategic restructuring, Vaccines

CSL; Seqirus; vaccine spin-off; workforce reduction; demerger; strategic restructuring; biotech; cost-cutting

High Drop-Out Rate Clouds Viking Therapeutics’ Oral Weight Loss Drug Trial Results

3 days ago talkbio0Tagged Clinical Trials, High Drop-Out Rate, oral obesity drug, treatment discontinuations, Viking, VK2735, weight loss data

Viking Therapeutics; oral obesity drug; VK2735; high drop-out rate; weight loss data; clinical trial; treatment discontinuations

FDA Rejection Derails PTC Therapeutics’ Rare Disease Hopeful

4 days ago talkbio0Tagged Clinical Trials, concerns, Effectiveness, factor IX, Failure (biologic function), Friedreich 's ataxia, Rare Diseases, Rejection, Response process, United States Food and Drug Administration, vatiquinone

PTC Therapeutics; FDA rejection; vatiquinone; Friedreich’s ataxia; rare disease; efficacy concerns; complete response letter; clinical trial failure

Stealth BioTherapeutics Resubmits Third FDA Application for Rare Disease Drug

4 days ago talkbio0Tagged 3-Methylglutaconic aciduria type 2, access program, Drug Approval, Elamipretide, Infrequent, resubmission, Stealth BioTherapeutics, United States Food and Drug Administration

Stealth BioTherapeutics; FDA resubmission; rare disease; Barth syndrome; elamipretide; drug approval; expanded access program

Battle Intensifies in the Obesity Drug Market as Novo Nordisk and Eli Lilly Vie for Dominance

4 days ago talkbio0Tagged Benefit, Clinical Trials, competition, Compounders, Direct-to-Consumer, eli lilly, Glucagon-Like Peptide 1, manager, Market, Nordisk, Obesity, Pharmaceutical Services, Wegovy, Zepbound

obesity drugs; GLP-1; Wegovy; Zepbound; Novo Nordisk; Eli Lilly; market competition; direct-to-consumer; pharmacy benefit managers; compounders; clinical trials

Shankar Ramaswamy’s Kriya Therapeutics Raises $313M for Gene Therapy Advancements

4 days ago talkbio0Tagged Biotechnology, gene therapy, Kriya, Shankar Ramaswamy, venture

Kriya Therapeutics; Shankar Ramaswamy; gene therapy; biotech funding; fundraising; biotechnology; venture capital; 2025